This model was constructed integrating the Fatty acid transporters (Homo sapiens) metapathway (WP5061), the Cholesterol metabolism (Homo sapiens) (WP5304) and the KEGG Cholesterol metabolism pathway (map04979) as well as information from the literature.
Comments
Fatty Acids and Cholesterol Transport
This model was constructed integrating the Fatty acid transporters (Homo sapiens) metapathway (WP5061), the Cholesterol metabolism (Homo sapiens) (WP5304) and the KEGG Cholesterol metabolism pathway (map04979) as well as information from the literature.
Curator:
Luiz Carlos Maia Ladeira, Biomechanics Research Unit, GIGA In Silico Medicine, University of Liège - Liège, Belgium.
Contributors:
Ramiro Jover, Dept. Biochemistry, University of Valencia, IIS Hosp. La Fe, CIBERehd, Spain
Jonas van Ertvelde, Department of In Vitro Toxicology and Dermato-cosmetology, Vrije Universiteit Brussel, Belgium
Sources:
Jeroen Kearns. (2021, February 26). Fatty acid transporters (Homo sapiens)—WikiPathways [Database]. Wikipathways. https://www.wikipathways.org/instance/WP5061
KEGG. (2022, July 7). KEGG PATHWAY: Cholesterol metabolism—Reference pathway [Database]. KEGG. https://www.kegg.jp/pathway/map04979
Nguyen, P., Leray, V., Diez, M., Serisier, S., Bloc’h, J. L., Siliart, B., and Dumon, H. (2008). Liver lipid metabolism. Journal of Animal Physiology and Animal Nutrition, 92(3), 272–283. https://doi.org/10.1111/j.1439-0396.2007.00752.x
Stahl, A. (2004). A current review of fatty acid transport proteins (SLC27). Pflügers Archiv, 447(5), 722–727. https://doi.org/10.1007/s00424-003-1106-z
Tom Pauly and Susan Coort. (2023, January 11). Cholesterol metabolism (Homo sapiens)—WikiPathways [Database]. Wikipathways. https://www.wikipathways.org/index.php/Pathway:WP5304
The chemical reactions and pathways resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.
A lipoprotein particle that is derived from a mature chylomicron particle by the removal of triglycerides from the chylomicron core by lipoprotein lipase and the subsequent loss of surface components. It characteristically contains apolipoprotein E (APOE) and is cleared from the blood by the liver.
A large lipoprotein particle (diameter 75-1200 nm) composed of a central core of triglycerides and cholesterol surrounded by a protein-phospholipid coating. The proteins include one molecule of apolipoprotein B-48 and may include a variety of apolipoproteins, including APOAs, APOCs and APOE. Chylomicrons are found in blood or lymph and carry lipids from the intestines into other body tissues.
Enables the transfer of a single solute from one side of a membrane to the other by a mechanism involving conformational change, either by facilitated diffusion or in a membrane potential dependent process if the solute is charged.
A vesicle-mediated transport process in which cells take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle.
A lipoprotein particle with a high density (typically 1.063-1.21 g/ml) and a diameter of 5-10 nm that contains APOAs and may contain APOCs and APOE; found in blood and carries lipids from body tissues to the liver as part of the reverse cholesterol transport process.
A triglyceride-rich lipoprotein particle that typically contains APOB100, APOE and APOCs and has a density of 1.006-1.019 g/ml and a diameter of between 25-30 nm. IDL particles are found in blood and are formed by the delipidation of very-low-density lipoprotein particles (VLDL). IDL particles are removed from blood by the liver, following binding to the APOE receptor, or are converted to low-density lipoprotein (LDL).
A lipoprotein particle, rich in cholesterol esters and low in triglycerides that is typically composed of APOB100 and APOE and has a density of 1.02-1.06 g/ml and a diameter of between 20-25 nm. LDL particles are formed from VLDL particles (via IDL) by the loss of triglyceride and gain of cholesterol ester. They transport endogenous cholesterol (and to some extent triglycerides) from peripheral tissues back to the liver.
A fatty acid oxidation process in which the methyl group at the end of the fatty acid molecule (the omega carbon) is first oxidized to a hydroxyl group, then to an oxo group, and finally to a carboxyl group. The long chain dicarboxylates derived from omega-oxidation then enter the beta-oxidation pathway for further degradation.
A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).
A lipoprotein particle with a high density (typically 1.063-1.21 g/ml) and a diameter of 5-10 nm that contains APOAs and may contain APOCs and APOE; found in blood and carries lipids from body tissues to the liver as part of the reverse cholesterol transport process.
A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).
A triglyceride-rich lipoprotein particle that is typically composed of APOB100, APOE and APOCs and has a density of about 1.006 g/ml and a diameter of between 20-80 nm. It is found in blood and transports endogenous products (newly synthesized cholesterol and triglycerides) from the liver.
This model was constructed integrating the Fatty acid transporters (Homo sapiens) metapathway (WP5061), the Cholesterol metabolism (Homo sapiens) (WP5304) and the KEGG Cholesterol metabolism pathway (map04979) as well as information from the literature.
Curator:
Luiz Carlos Maia Ladeira, Biomechanics Research Unit, GIGA In Silico Medicine, University of Liège - Liège, Belgium.
Contributors:
Ramiro Jover, Dept. Biochemistry, University of Valencia, IIS Hosp. La Fe, CIBERehd, Spain
Jonas van Ertvelde, Department of In Vitro Toxicology and Dermato-cosmetology, Vrije Universiteit Brussel, Belgium
Sources:
Jeroen Kearns. (2021, February 26). Fatty acid transporters (Homo sapiens)—WikiPathways [Database]. Wikipathways. https://www.wikipathways.org/instance/WP5061
KEGG. (2022, July 7). KEGG PATHWAY: Cholesterol metabolism—Reference pathway [Database]. KEGG. https://www.kegg.jp/pathway/map04979
Nguyen, P., Leray, V., Diez, M., Serisier, S., Bloc’h, J. L., Siliart, B., and Dumon, H. (2008). Liver lipid metabolism. Journal of Animal Physiology and Animal Nutrition, 92(3), 272–283. https://doi.org/10.1111/j.1439-0396.2007.00752.x
Stahl, A. (2004). A current review of fatty acid transport proteins (SLC27). Pflügers Archiv, 447(5), 722–727. https://doi.org/10.1007/s00424-003-1106-z
Tom Pauly and Susan Coort. (2023, January 11). Cholesterol metabolism (Homo sapiens)—WikiPathways [Database]. Wikipathways. https://www.wikipathways.org/index.php/Pathway:WP5304
Try the New WikiPathways
View approved pathways at the new wikipathways.org.Quality Tags
Ontology Terms
Bibliography
History
External references
DataNodes
Annotated Interactions